JAK2 and mantle cell lymphoma: Importantly, the ex vivo screen also demonstrated that protein kinase inhibitors targeting JAK1, JAK2, aurora A, IGF1R and PLK suppressed cell growth of IR MCL cells (Fig. 6e).